Alimta Indications/Uses

Malignant pleural mesothelioma: ALIMTA in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer: ALIMTA in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions).
ALIMTA is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see Pharmacology: Pharmacodynamics under Actions).
ALIMTA is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non‑small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions).